Huyen Nguyen: Highlights from the NCCN Cancer-Associated Venous Thromboembolic Disease Guidelines
Huyen Nguyen, Clinical Pharmacist at Vinmec Healthcare System, shared on LinkedIn:
”NCCN Cancer-Associated Venous Thromboembolic Disease Guidelines Version 1.2026
Venous thromboembolism (VTE) remains one of the most common and potentially life-threatening complications in patients with cancer.
It is associated with increased morbidity, treatment interruptions, hospitalisations, and mortality.
Some important clinical updates and reminders:
- Cancer increases the risk of VTE several-fold compared with the general population, making risk assessment an essential component of routine oncology care.
- The Khorana Score remains one of the most validated tools for identifying ambulatory patients at high risk for chemotherapy-associated thrombosis.
- Direct oral anticoagulants (DOACs), including apixaban and rivaroxaban, are increasingly used for both thromboprophylaxis and treatment of cancer-associated thrombosis in appropriately selected patients.
- Extended thromboprophylaxis should be considered following major abdominal or pelvic cancer surgery in patients at high risk of postoperative VTE.
- Catheter-related thrombosis can often be managed with anticoagulation without immediate catheter removal when the device remains functional and clinically necessary.
Some practical clinical pearls:
- Assess thrombosis and bleeding risk before initiating anticoagulation
- Review renal function, hepatic function, platelet count, and drug interactions regularly
- Consider LMWH in selected patients with severe thrombocytopenia, gastrointestinal malignancies, genitourinary cancers, or concerns regarding DOAC absorption
- Evaluate interactions with targeted therapies, azole antifungals, anticonvulsants, and other CYP/P-gp modulators
- Reassess anticoagulation needs periodically as cancer status, treatment plans, and bleeding risks evolve
- Remember that active cancer often represents a persistent thrombotic risk factor, and anticoagulation beyond 3 months may be appropriate for selected patients
Another important reminder:
Optimal management of cancer-associated thrombosis requires multidisciplinary collaboration among oncologists, hematologists, pharmacists, surgeons, nurses, and thrombosis specialists to maximize efficacy while minimizing bleeding complications.”
Stay updated with Hemostasis Today.
-
Sep 6, 2026, 18:17Aryabhatta Sadhu: Irradiation of Blood Components – From Clinical Indication to Laboratory Release
-
Sep 6, 2026, 18:15Ashenafi Tazebew Amare: A Year of Progress, Transformation and Renewed Commitment
-
Sep 6, 2026, 18:13Emilio Osorio: Can Anticoagulation Be Safely Discontinued After Surgical Left Atrial Appendage Occlusion?
-
Sep 6, 2026, 18:11Razan Alolyani: Our Research on Anticoagulation After Acute Ischemic Stroke Receives 2nd Place
-
Sep 6, 2026, 18:10Chayakrit Krittanawong: Have You Heard of Blood Clots in the Legs?
-
Sep 6, 2026, 18:08Trilok Chand: Microplastics Found in Human Testes and Blood Clots
-
Sep 6, 2026, 18:07Sarah Moharem Elgamal: Cardiovascular Imaging Beyond Anatomy Toward Earlier Risk Prediction
-
Sep 6, 2026, 16:41Christina (Tina) P.: APS – How it Happens in Your Blood, the Warning Signs, and What to Do about It
-
Sep 6, 2026, 16:33Jose Angel Nicolas Avila: How Tissue Mitochondrial Activity Dictates Macrophage Pool Size